Search academic texts

Information × Registration Number 0221U104886, 0119U000579 , R & D reports Title Identify ways to reduce the disability of patients with giant cell disease of bones on the basis of targeted therapy and optimization of surgical treatment popup.stage_title Head Diedkov Anatolii H., Registration Date 26-04-2021 Organization National Cancer Institute popup.description2 Object of study: patients with giant cell bone tumors. A retrospective analysis of the treatment of patients with giant cell tumor (GCP) with localization in long bones treated for the period from 1977 to 2012 was performed. The study included 142 patients, of whom 70 patients underwent surgical treatment in the form of excochleation (intraosseous resection) (BP) with filling of the defect with bone grafts or biodegradable materials and 72 patients with GCP after extensive resection (SR) with reconstruction of the defect. In the group of patients who underwent BP local recurrences were detected in 35.7%, which is 7 times higher than in the group of HR. The functional result for MSTS of the operated limb in patients in this group was 92.5%, in the SR group 78.8% (p = 0.02). Clinical factors such as intraosseous resection, the location of the tumor in the distal radial bone, and the patient's age up to 25 years, Campanacci stage III are strongly associated with local recurrence. For patients after BP, the recurrence-free survival rate was 71.0%, for patients after HR - 95.8% (p = 0.001). According to the developed methods with the use of denosumab, 58 patients with HCC were treated. 47 patients were treated with neoadjuvant targeted therapy (TT), conservative surgery and subsequent adjuvant therapy. Another 11 patients with GCP did not undergo surgery due to refusal to intervene or at risk of significant functional disorders associated with the operation (sacrum). Complications with the introduction of denosumab were not observed in any case. The number of local recurrences is 10 out of 47 (21.2%) on average after 25.8 months. Of these, 3 patients (100.0%) were localized in the distal radial bone. In the group of patients without surgical treatment - disease progression was observed in two patients with a median follow-up (34.5 ± 6.2) months.   Product Description popup.authors Boichuk Serhii I. Kostiuk Viktor Yu. Maksymenko Bohdan V. popup.nrat_date 2021-04-26 Close